FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950277551> ?p ?o ?g. }

• W2950277551 endingPage "718" @default.
• W2950277551 startingPage "718" @default.
• W2950277551 abstract "Background: Novel insights into the pathophysiology of GVHD highlighted the relevant role of the host inflammatory response governed by Bruton tyrosine kinase (BTK) signaling pathway. Ibrutinib is a first class, once daily inhibitor of BTK with proven efficacy in B cell lympho-proliferative diseases, was recently employed in corticosteroid- refractory chronic GVHD with encouraging overall response rates(Miklos et all, Blood 2017). We previously reported the results of 14 patients who received ibrutinib treatment for steroid-refractory cGVHD (Ilhan et all, ASH 2018) Aims: Herein, we share a real-life experience using ibrutinib in the treatment of streoid-refractory cGVHD in 30 patients from centers in Turkey. Methods: This multicenter retrospective study conducted in 9 stem cell transplant centers from Turkey included 30 adult patients diagnosed with steroid-refractory cGVHD. We treated off-label these patients from June 2017 to July 2018 with ibrutinib with a dose of 420 mg P.O. qday. Organ sites affected and cGVHD grading before starting ibrutinib were classified according to the National Institues of Health (NIH) 2014 criteria. Steroid refractory cGVHD was defined as any disease that failed to respond to previous immunosuppressive therapy with steroids at least 4 weeks or inability to taper it with or without additional immunosuppressive drugs. Results: The baseline characteristics of the patients are listed in Table 1. Patients had undergone both myeloablative and non-myeloablative Allo-SCT for a variety of underlying hematological malignancies. As expected mouth and skin were the most frequently involved organs and 56.7 % of patients showed evidence of cGVHD in more than 2 organs. The median Karnofsky Performance Status score was 65% (20%>100%). At a median follow-up of 22.3 months (range, 7.1–109 months) after evidence of cGVHD showed, 27 (90%) patients were still receiving ibrutinib and 3 (10%) had discontinued treatment, because of cGVHD progression. Treatment duration ranged from 2 to 12 months (median 6 months) for all patients. Only three patients had grade 2 muscle spasm, arrhythmia and diarrhea as adverse events and need to reduce the 25% of drug dosage. No several adverse events due to ibrutinib were observed in our cohort. In the all treated population, the overall response rate (ORR), based on the 2005 NIH cGVHD Consensus Panel response criteria, was 63.3%, with a CR rate of 23.3 % and a PR rate of 40 %. For the responders, the median time to initial response was 28 days. Five patients had stable disease under the ibrutinib treatment and still continue receiving. Analysis by organ domain showed similar rates of response in the skin (91.7%), lung (85.7%) and mouth (80%). However the response in the liver (71.4%) was lower than the others. At the time of data collection, three patient had deceased.Summary/Conclusion: Based on the results of our study; the clinically meaningful response with safety profile observed with ibrutinib as a salvage therapy for chronic GVHD in accordance with Miklos and colleagues's report. However, in contrast to their results; patients with skin and lung manifestations of cGVHD were appeared to have somewhat better responses to ibrutinib than patients with cGVHD involving liver. It is important to note that prospective randomized controlled studies with large number of patients are warranted to find out the standard regimen for steroid-refractory cGVHD." @default.
• W2950277551 created "2019-06-27" @default.
• W2950277551 creator A5004588913 @default.
• W2950277551 creator A5006593426 @default.
• W2950277551 creator A5011023287 @default.
• W2950277551 creator A5014800900 @default.
• W2950277551 creator A5016835638 @default.
• W2950277551 creator A5030401832 @default.
• W2950277551 creator A5043084722 @default.
• W2950277551 creator A5043984651 @default.
• W2950277551 creator A5058571002 @default.
• W2950277551 creator A5059752205 @default.
• W2950277551 creator A5061471763 @default.
• W2950277551 creator A5072344712 @default.
• W2950277551 creator A5076735212 @default.
• W2950277551 date "2019-06-01" @default.
• W2950277551 modified "2023-10-14" @default.
• W2950277551 title "PS1556 BRUTON TYROSINE KINASE INHIBITOR IS AN EFFECTIVE STEROID-SPARING AGENT IN CHRONIC GRAFT-VERSUS-HOST DISEASE" @default.
• W2950277551 doi "https://doi.org/10.1097/01.hs9.0000564480.84127.74" @default.
• W2950277551 hasPublicationYear "2019" @default.
• W2950277551 type Work @default.
• W2950277551 sameAs 2950277551 @default.
• W2950277551 citedByCount "1" @default.
• W2950277551 countsByYear W29502775512021 @default.
• W2950277551 crossrefType "journal-article" @default.
• W2950277551 hasAuthorship W2950277551A5004588913 @default.
• W2950277551 hasAuthorship W2950277551A5006593426 @default.
• W2950277551 hasAuthorship W2950277551A5011023287 @default.
• W2950277551 hasAuthorship W2950277551A5014800900 @default.
• W2950277551 hasAuthorship W2950277551A5016835638 @default.
• W2950277551 hasAuthorship W2950277551A5030401832 @default.
• W2950277551 hasAuthorship W2950277551A5043084722 @default.
• W2950277551 hasAuthorship W2950277551A5043984651 @default.
• W2950277551 hasAuthorship W2950277551A5058571002 @default.
• W2950277551 hasAuthorship W2950277551A5059752205 @default.
• W2950277551 hasAuthorship W2950277551A5061471763 @default.
• W2950277551 hasAuthorship W2950277551A5072344712 @default.
• W2950277551 hasAuthorship W2950277551A5076735212 @default.
• W2950277551 hasBestOaLocation W29502775511 @default.
• W2950277551 hasConcept C126322002 @default.
• W2950277551 hasConcept C142424586 @default.
• W2950277551 hasConcept C143998085 @default.
• W2950277551 hasConcept C170493617 @default.
• W2950277551 hasConcept C2777938653 @default.
• W2950277551 hasConcept C2778461978 @default.
• W2950277551 hasConcept C2779134260 @default.
• W2950277551 hasConcept C2779878957 @default.
• W2950277551 hasConcept C2779972918 @default.
• W2950277551 hasConcept C42362537 @default.
• W2950277551 hasConcept C71924100 @default.
• W2950277551 hasConcept C86803240 @default.
• W2950277551 hasConcept C87355193 @default.
• W2950277551 hasConcept C90059517 @default.
• W2950277551 hasConceptScore W2950277551C126322002 @default.
• W2950277551 hasConceptScore W2950277551C142424586 @default.
• W2950277551 hasConceptScore W2950277551C143998085 @default.
• W2950277551 hasConceptScore W2950277551C170493617 @default.
• W2950277551 hasConceptScore W2950277551C2777938653 @default.
• W2950277551 hasConceptScore W2950277551C2778461978 @default.
• W2950277551 hasConceptScore W2950277551C2779134260 @default.
• W2950277551 hasConceptScore W2950277551C2779878957 @default.
• W2950277551 hasConceptScore W2950277551C2779972918 @default.
• W2950277551 hasConceptScore W2950277551C42362537 @default.
• W2950277551 hasConceptScore W2950277551C71924100 @default.
• W2950277551 hasConceptScore W2950277551C86803240 @default.
• W2950277551 hasConceptScore W2950277551C87355193 @default.
• W2950277551 hasConceptScore W2950277551C90059517 @default.
• W2950277551 hasIssue "S1" @default.
• W2950277551 hasLocation W29502775511 @default.
• W2950277551 hasLocation W29502775512 @default.
• W2950277551 hasOpenAccess W2950277551 @default.
• W2950277551 hasPrimaryLocation W29502775511 @default.
• W2950277551 hasRelatedWork W2018466312 @default.
• W2950277551 hasRelatedWork W2047415399 @default.
• W2950277551 hasRelatedWork W2073700560 @default.
• W2950277551 hasRelatedWork W2557815702 @default.
• W2950277551 hasRelatedWork W3030489043 @default.
• W2950277551 hasRelatedWork W3093992023 @default.
• W2950277551 hasRelatedWork W3106592852 @default.
• W2950277551 hasRelatedWork W3119564337 @default.
• W2950277551 hasRelatedWork W3210817501 @default.
• W2950277551 hasRelatedWork W3213562847 @default.
• W2950277551 hasVolume "3" @default.
• W2950277551 isParatext "false" @default.
• W2950277551 isRetracted "false" @default.
• W2950277551 magId "2950277551" @default.
• W2950277551 workType "article" @default.